PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
18724382-10	2008	Furthermore, stimulation of MRP4-mediated renal urate efflux could be a new mechanism in the hypouricaemic action of allopurinol and oxypurinol.	Oxypurinol	133-143	ATP binding cassette subfamily C member 4	Homo sapiens	28-32
18724382-6	2008	KEY RESULTS: Allopurinol stimulated MRP4-mediated cellular urate efflux and allopurinol and oxypurinol both markedly stimulated urate transport by MRP4 in membrane vesicles.	Oxypurinol	92-102	ATP binding cassette subfamily C member 4	Homo sapiens	147-151
19037590-11	2008	Inhibition of nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase by apocynin decreased vascular superoxide formation whereas the xanthine oxidase inhibitor oxypurinol did not significantly affect oxidative stress in LDLR(-/-) mice.	Oxypurinol	165-175	xanthine dehydrogenase	Mus musculus	138-154
18995179-1	2008	The purine analog xanthine oxidase (XO) inhibitors (XOIs), allopurinol and oxypurinol, have been reported to protect against heart failure secondary to myocardial infarction or rapid ventricular pacing.	Oxypurinol	75-85	xanthine dehydrogenase	Mus musculus	18-34
18653825-3	2008	O(2)(*-) stimulated by NTG was reduced by oxypurinol (100 microM), a xanthine oxidase inhibitor.	Oxypurinol	42-52	xanthine dehydrogenase	Mus musculus	69-85
18569334-12	2008	The NAD+ dependent retinol oxidation catalyzed by xanthine dehydrogenase is strictly dependent on cellular retinol binding proteins and is inhibited by oxypurinol.	Oxypurinol	152-162	xanthine dehydrogenase	Homo sapiens	50-72
18600558-0	2008	Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol.	Oxypurinol	143-153	xanthine dehydrogenase	Bos taurus	27-50
18600558-0	2008	Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol.	Oxypurinol	143-153	xanthine dehydrogenase	Bos taurus	108-131
18600558-2	2008	We determined the crystal structure of reduced bovine milk xanthine oxidoreductase complexed with oxipurinol at 2.0 A resolution.	Oxypurinol	98-108	xanthine dehydrogenase	Bos taurus	59-82
18386220-7	2008	In contrast, application of the XO inhibitor oxypurinol or allopurinol inhibited VEGF-stimulated Akt phosphorylation, indicating that endogenous XO promotes VEGF-induced endothelial cell (EC) survival signaling.	Oxypurinol	45-55	vascular endothelial growth factor A	Homo sapiens	81-85
18386220-7	2008	In contrast, application of the XO inhibitor oxypurinol or allopurinol inhibited VEGF-stimulated Akt phosphorylation, indicating that endogenous XO promotes VEGF-induced endothelial cell (EC) survival signaling.	Oxypurinol	45-55	AKT serine/threonine kinase 1	Homo sapiens	97-100
18386220-7	2008	In contrast, application of the XO inhibitor oxypurinol or allopurinol inhibited VEGF-stimulated Akt phosphorylation, indicating that endogenous XO promotes VEGF-induced endothelial cell (EC) survival signaling.	Oxypurinol	45-55	vascular endothelial growth factor A	Homo sapiens	157-161
18344696-3	2008	Its activity is largely the result of the inhibition of xanthine oxidoreductase by oxypurinol, the active metabolite of allopurinol.	Oxypurinol	83-93	xanthine dehydrogenase	Homo sapiens	56-79
17709654-6	2007	Cardiac xanthine oxidoreductase inhibition with oxypurinol significantly reduced cardiac superoxide, prevented the progression of cardiac remodeling, and delayed the mortality in DS rats.	Oxypurinol	48-58	xanthine dehydrogenase	Rattus norvegicus	8-31
17963680-6	2007	Further, oxypurinol was given to patients undergoing coronary angioplasty, a procedure known to increase plasma endothelin-1 concentrations.	Oxypurinol	9-19	endothelin 1	Homo sapiens	112-124
17963680-8	2007	Patients undergoing coronary angioplasty exhibited significantly elevated big endothelin-1 concentrations 60 minutes after angioplasty (p = .03); in patients also receiving oxypurinol immediately after angioplasty, big endothelin-1 concentrations decreased (p = .001).	Oxypurinol	173-183	endothelin 1	Homo sapiens	219-231
16357304-8	2006	Importantly, SHHF rats exhibited increased XOR mRNA expression and activity, and oxypurinol treatment reduced XOR activity and superoxide production toward normal, but not expression.	Oxypurinol	81-91	xanthine dehydrogenase	Rattus norvegicus	110-113
16135657-9	2005	These results indicate that URAT1 is involved in renal reabsorption of oxypurinol, and the increment of renal clearance of oxypurinol upon concomitant administration of benzbromarone could be due to drug interaction at URAT1.	Oxypurinol	71-81	solute carrier family 22 member 12	Homo sapiens	28-33
16135657-9	2005	These results indicate that URAT1 is involved in renal reabsorption of oxypurinol, and the increment of renal clearance of oxypurinol upon concomitant administration of benzbromarone could be due to drug interaction at URAT1.	Oxypurinol	123-133	solute carrier family 22 member 12	Homo sapiens	219-224
16382292-4	2005	Allopurinol and oxypurinol inhibit xanthine oxidoreductase and thus diminish the generation of reactive species and decrease plasma uric acid.	Oxypurinol	16-26	xanthine dehydrogenase	Homo sapiens	35-58
16243586-6	2005	Treatment with TEMPOL, human superoxide dismutase, diphenyleneiodonium, oxypurinol, NG-monomethyl L-arginine considerably decreased contractile response to angiotensin II in radial arteries.	Oxypurinol	72-82	angiotensinogen	Homo sapiens	156-170
15932950-3	2005	Inhibitors of aldehyde oxidase markedly inhibited these nitroreductase activities, but oxypurinol, an inhibitor of xanthine oxidoreductase, had little effect.	Oxypurinol	87-97	xanthine dehydrogenase	Homo sapiens	115-138
15637297-9	2005	The attenuated bradykinin-induced reduction in MVO2 in nNOS-/- was restored by preincubation with Tiron, ascorbic acid, Tempol, oxypurinol, or SB203850, an inhibitor of p38 kinase, but not apocynin.	Oxypurinol	128-138	nitric oxide synthase 1, neuronal	Mus musculus	55-59
15637297-9	2005	The attenuated bradykinin-induced reduction in MVO2 in nNOS-/- was restored by preincubation with Tiron, ascorbic acid, Tempol, oxypurinol, or SB203850, an inhibitor of p38 kinase, but not apocynin.	Oxypurinol	128-138	mitogen-activated protein kinase 14	Mus musculus	169-172
15264228-8	2004	Notably, cytotoxicity by M239V-PS2 could be inhibited by the combination of two clinically usable inhibitors of superoxide-generating enzymes, apocynin and oxypurinol.	Oxypurinol	156-166	presenilin 2	Homo sapiens	31-34
15213626-5	2004	RESULTS: Oxypurinol prevented p38 phosphorylation in the pancreas and partially avoided the rise in lung myeloperoxidase activity.	Oxypurinol	9-19	mitogen activated protein kinase 14	Rattus norvegicus	30-33
15213626-7	2004	Combined treatment with oxypurinol and pentoxifylline almost completely abolished ascites, MAPK phosphorylation in the pancreas, and the increase in lung myeloperoxidase activity.	Oxypurinol	24-34	mitogen activated protein kinase 3	Rattus norvegicus	91-95
14694147-8	2004	Importantly, the XOR inhibitors allopurinol and oxypurinol attenuate dysfunction caused by XOR in these disease states.	Oxypurinol	48-58	xanthine dehydrogenase	Homo sapiens	17-20
14694147-8	2004	Importantly, the XOR inhibitors allopurinol and oxypurinol attenuate dysfunction caused by XOR in these disease states.	Oxypurinol	48-58	xanthine dehydrogenase	Homo sapiens	91-94
14499859-9	2003	Failing rat myocardium exhibited higher XOR activity than nonfailing myocardium, and this activity was largely suppressed in oxypurinol-treated preparations.	Oxypurinol	125-135	xanthine dehydrogenase	Rattus norvegicus	40-43
14499859-11	2003	Specifically, the inotropic actions of oxypurinol are more pronounced in failing rat myocardium, a tissue that exhibits enhanced XOR activity.	Oxypurinol	39-49	xanthine dehydrogenase	Rattus norvegicus	129-132
12077737-0	2002	Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol.	Oxypurinol	74-84	angiotensinogen	Homo sapiens	11-25
12077737-1	2002	The effect of angiotensin II infusion on the renal transport of purine bases and oxypurinol (a metabolite of allopurinol) was investigated in 5 healthy subjects who were orally given allopurinol (300 mg) 9 hours prior to the study.	Oxypurinol	81-91	angiotensinogen	Homo sapiens	14-28
12077737-3	2002	The fractional clearances of uric acid, xanthine, and oxypurinol were significantly decreased during angiotensin II infusion; however, that of hypoxanthine did not change.	Oxypurinol	54-64	angiotensinogen	Homo sapiens	101-115
12077737-4	2002	The urinary excretion levels of uric acid, xanthine, and oxypurinol were also significantly decreased during angiotensin II infusion.	Oxypurinol	57-67	angiotensinogen	Homo sapiens	109-123
12077737-5	2002	These results suggest that angiotensin II infusion affected the renal clearances of uric acid, xanthine, and oxypurinol through direct tubular transport and/or hemodynamic changes.	Oxypurinol	109-119	angiotensinogen	Homo sapiens	27-41
12076093-7	2002	Significant MREC protection was achieved by the superoxide scavengers SOD (1000 U ml(-1)) and a carboxylic acid derivative of carboxyfullerene (10 microM), the xanthine oxidase inhibitors oxypurinol (100 microM) and diphenyleneiodonium (DPI) (100 n M), and the cyclooxygenase inhibitors indomethacin (300 microM) and ibuprofen (300 microM).	Oxypurinol	188-198	xanthine dehydrogenase	Mus musculus	160-176
11796116-5	2002	As a hypoxanthine analog, it is oxidized to alloxanthine, which cannot be further oxidized but acts as a tight binding inhibitor of XDH.	Oxypurinol	44-56	xanthine dehydrogenase	Bos taurus	132-135
11796116-6	2002	The 3.0 A resolution structure of the XDH-alloxanthine complex shows direct coordination of alloxanthine to the molybdenum via a nitrogen atom.	Oxypurinol	42-54	xanthine dehydrogenase	Bos taurus	38-41
11796116-6	2002	The 3.0 A resolution structure of the XDH-alloxanthine complex shows direct coordination of alloxanthine to the molybdenum via a nitrogen atom.	Oxypurinol	92-104	xanthine dehydrogenase	Bos taurus	38-41
11173071-3	2001	Allopurinol and oxypurinol, but not superoxide dismutase or catalase, protected the gastric mucosa 24 h after endothelin-1 injection.	Oxypurinol	16-26	endothelin 1	Rattus norvegicus	110-122
11173071-4	2001	Oxypurinol antagonized both the vasoconstrictor effect of endothelin-1 and the decrease in gastric ATP.	Oxypurinol	0-10	endothelin 1	Rattus norvegicus	58-70
11230310-4	2001	Preincubation with the XOR inhibitor oxypurinol also improved endothelium-dependent vascular relaxation.	Oxypurinol	37-47	xanthine dehydrogenase	Homo sapiens	23-26
10891374-7	2000	Oxypurinol and the antibody against P-selectin prevented pancreatitis-induced lung Hsp72 overexpression suggesting that Hsp72 induction is mediated by neutrophil infiltration into the lungs.	Oxypurinol	0-10	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	83-88
10481935-6	1999	Allopurinol was metabolized to oxypurinol and pyrazinamide to 5-hydroxypyrazinamide in spite of no activity of xanthine oxidase, suggesting that aldehyde oxidase converted allopurinol to oxypurinol and pyrazinamide to 5-hydroxypyrazinamide.	Oxypurinol	31-41	aldehyde oxidase 1	Homo sapiens	145-161
10481935-6	1999	Allopurinol was metabolized to oxypurinol and pyrazinamide to 5-hydroxypyrazinamide in spite of no activity of xanthine oxidase, suggesting that aldehyde oxidase converted allopurinol to oxypurinol and pyrazinamide to 5-hydroxypyrazinamide.	Oxypurinol	187-197	aldehyde oxidase 1	Homo sapiens	145-161
9727720-5	1998	Treatment with oxypurinol reduced the aspartate aminotransferase, alanine aminotransferase, and bilirubin values by 26-47% but did not alter the increased lipid peroxidation of mitochondria and microsomes.	Oxypurinol	15-25	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	38-64
9510406-5	1998	The conversion of allopurinol to oxipurinol during an allopurinol loading test for determining the type of classical xanthinuria revealed that the patients had classical type 1 xanthinuria, because aldehyde oxidase activity was present.	Oxypurinol	33-43	aldehyde oxidase 1	Homo sapiens	198-214
9288448-11	1997	Pre-ischemic inhibition of xanthine oxidase/xanthine dehydrogenase by oxypurinol (40 or 80 mg/kg intraperitoneally [IP]) resulted in a significant improvement in recovery of the a and b waves of the electroretinogram in comparison to a saline-treated control group.	Oxypurinol	70-80	xanthine dehydrogenase	Rattus norvegicus	44-66
9028164-10	1997	In vitro co-culture indicated that CFU-G, E, and Meg in the bone marrow cells after recovery from pancytopenia were markedly suppressed in the presence of patient"s serum and oxipurinol.	Oxypurinol	175-185	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	49-52
8687488-9	1996	ONOO- synthesized by NO and O2- following UVB radiation of cNOS and XO was inhibited by oxypurinol (100 microM).	Oxypurinol	88-98	nitric oxide synthase 3	Homo sapiens	59-63
8695568-14	1996	Allopurinol and oxypurinol act as direct scavengers of free radicals and hypochlorous acid, which is produced via MPO catalysis, thus leading to a reduction in tissue inflammation and tissue damage.	Oxypurinol	16-26	myeloperoxidase	Homo sapiens	114-117
7649493-6	1995	The ESR signal was insensitive to the xanthine oxidase inhibitor, oxypurinol, or to superoxide dismutase, but was eliminated in a concentration-dependent manner by either potassium cyanide or catalase (but not heat-inactivated catalase).	Oxypurinol	66-76	catalase	Rattus norvegicus	192-200
7519008-4	1994	Xanthine-induced lipofuscin formation could be inhibited by oxypurinol, indicating that the pigment may be formed by free radicals generated by xanthine dehydrogenase.	Oxypurinol	60-70	xanthine dehydrogenase	Homo sapiens	144-166
8267672-1	1993	The uricostatic drug allopurinol (CAS 315-30-0) is used for treatment of hyperuricaemia and is mainly bio-transformed to the active metabolite oxipurinol (CAS 2465-59-0) in humans.	Oxypurinol	143-153	BCAR1 scaffold protein, Cas family member	Homo sapiens	34-37
8267672-1	1993	The uricostatic drug allopurinol (CAS 315-30-0) is used for treatment of hyperuricaemia and is mainly bio-transformed to the active metabolite oxipurinol (CAS 2465-59-0) in humans.	Oxypurinol	143-153	BCAR1 scaffold protein, Cas family member	Homo sapiens	155-158
8216357-7	1993	These results suggest that aldehyde oxidase may play a role in the oxidation of allopurinol to oxypurinol and that of pyrazinamide to 5-hydroxypyrazinamide with xanthine dehydrogenase which can oxidize both allopurinol and pyrazinamide in vivo.	Oxypurinol	95-105	aldehyde oxidase 1	Homo sapiens	27-43
8441835-7	1993	In animals given oxypurinol at 5 mg/kg BW 40 min after ischemia, the CIn was significantly greater than in those receiving buffered saline.	Oxypurinol	17-27	Body weight QTL 40	Rattus norvegicus	39-44
1541673-11	1992	Pretreatment with 0.5 mM oxypurinol attenuated the synergistic effect of TNF alpha and H2O2 on endothelial permeability.	Oxypurinol	25-35	tumor necrosis factor	Bos taurus	73-82
2323062-2	1990	This study provides evidence that the enzyme aldehyde oxidase is also deficient in xanthinuric patients not converting allopurinol to oxipurinol, whereas a xanthinuric patient with normal formation of oxipurinol had normal aldehyde oxidase activity.	Oxypurinol	134-144	aldehyde oxidase 1	Homo sapiens	45-61
2323062-2	1990	This study provides evidence that the enzyme aldehyde oxidase is also deficient in xanthinuric patients not converting allopurinol to oxipurinol, whereas a xanthinuric patient with normal formation of oxipurinol had normal aldehyde oxidase activity.	Oxypurinol	201-211	aldehyde oxidase 1	Homo sapiens	45-61
2323062-3	1990	It is concluded that the enzyme aldehyde oxidase is the principal enzyme responsible for the formation of oxipurinol in man.	Oxypurinol	106-116	aldehyde oxidase 1	Homo sapiens	32-48
2167267-6	1990	Experiments using oxyupurinol, SOD, CAT and a combination of SOD and CAT show that while oxypurinol partially prevents spin adduct formation, the combination of SOD and CAT is more effective in doing so.	Oxypurinol	89-99	catalase	Homo sapiens	36-39
2167267-6	1990	Experiments using oxyupurinol, SOD, CAT and a combination of SOD and CAT show that while oxypurinol partially prevents spin adduct formation, the combination of SOD and CAT is more effective in doing so.	Oxypurinol	89-99	catalase	Homo sapiens	69-72
2167267-6	1990	Experiments using oxyupurinol, SOD, CAT and a combination of SOD and CAT show that while oxypurinol partially prevents spin adduct formation, the combination of SOD and CAT is more effective in doing so.	Oxypurinol	89-99	catalase	Homo sapiens	69-72
35163565-7	2022	As the PPARD mice aged from 10 weeks to 35 weeks and 55 weeks, we observed significant changes in levels of the metabolites inosine monophosphate (p = 0.0054), adenosine monophosphate (p = 0.009), UDP-glucose (p = 0.0006), and oxypurinol (p = 0.039).	Oxypurinol	227-237	peroxisome proliferator activator receptor delta	Mus musculus	7-12
2557043-3	1989	It formed an initial complex with electron-rich (reduced) human xanthine oxidase that was tighter than the corresponding complex formed by oxypurinol.	Oxypurinol	139-149	xanthine dehydrogenase	Mus musculus	64-80
2557043-11	1989	Compared to the inhibition of xanthine oxidase by oxypurinol, inhibition by B103U was neither more potent nor longer lasting.	Oxypurinol	50-60	xanthine dehydrogenase	Mus musculus	30-46
2757114-8	1989	The basal XO and XD activities and the neutrophil-induced increase in XO activity were inhibited by treating RPAECs with allopurinol, oxypurinol, and lodoxamide, which also inhibited cytotoxicity, but not by catalase, superoxide dismutase, or deferoxamine.	Oxypurinol	134-144	catalase	Rattus norvegicus	208-216
3396300-16	1988	Addition of the xanthine oxidase inhibitor oxypurinol at a luminal concentration of 0.3 mmol/l prevented the formation of 6-thiouric acid from 6-thioguanine.	Oxypurinol	43-53	xanthine dehydrogenase	Mus musculus	16-32
2823807-0	1987	Role of xanthine oxidase inhibitor as free radical scavenger: a novel mechanism of action of allopurinol and oxypurinol in myocardial salvage.	Oxypurinol	109-119	xanthine dehydrogenase	Sus scrofa	8-24
668894-0	1978	Effects of allopurinol and of oxypurinol on turkey liver xanthine dehydrogenase.	Oxypurinol	30-40	xanthine dehydrogenase/oxidase	Meleagris gallopavo	57-79
5032526-4	1972	"Activation" of the OPRT enzyme was directly demonstrated in erythrocytes studied in vitro after incubation with oxipurinol, and to a lesser extent, with allopurinol.	Oxypurinol	113-123	uridine monophosphate synthetase	Homo sapiens	20-24
33931953-0	2021	Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.	Oxypurinol	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	85-89
33931953-2	2021	Using a multifaceted approach, we aimed to characterize the relationship(s) between BCRP p.Q141K, the pharmacokinetics (PK) and pharmacodynamics (PD) of oxypurinol (the active metabolite of allopurinol), and serum uric acid (SUA) levels.	Oxypurinol	153-163	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	84-88
31990564-7	2020	Only one of the 26 inhibitors of BCRP identified in vesicles inhibited BCRP-mediated 3H-oxypurinol uptake by more than 50%, consistent with the notion that BCRP inhibition depends on transmembrane or intracellular availability of the inhibitors.	Oxypurinol	85-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	33-37
31990564-7	2020	Only one of the 26 inhibitors of BCRP identified in vesicles inhibited BCRP-mediated 3H-oxypurinol uptake by more than 50%, consistent with the notion that BCRP inhibition depends on transmembrane or intracellular availability of the inhibitors.	Oxypurinol	85-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	71-75
31990564-7	2020	Only one of the 26 inhibitors of BCRP identified in vesicles inhibited BCRP-mediated 3H-oxypurinol uptake by more than 50%, consistent with the notion that BCRP inhibition depends on transmembrane or intracellular availability of the inhibitors.	Oxypurinol	85-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	71-75
31444839-12	2020	Although there is a positive relationship between change in oxypurinol and change in SU concentration, a minimum therapeutic oxypurinol is dependent on CrCL and cannot reliably predict SU target.	Oxypurinol	125-135	CRCL	Homo sapiens	152-156
30924126-7	2019	In vitro studies identified oxypurinol, the active metabolite of allopurinol, as an inhibitor of the UA transporter GLUT9, suggesting that oxypurinol may modulate UA reabsorption.	Oxypurinol	28-38	solute carrier family 2 member 9	Homo sapiens	116-121
30924126-7	2019	In vitro studies identified oxypurinol, the active metabolite of allopurinol, as an inhibitor of the UA transporter GLUT9, suggesting that oxypurinol may modulate UA reabsorption.	Oxypurinol	139-149	solute carrier family 2 member 9	Homo sapiens	116-121
31140171-3	2019	An alternative process in which nitrated fatty acids may extend anti-inflammatory actions is via inactivation of XOR, a process that is more effective than allo/oxypurinol-mediated inhibition.	Oxypurinol	161-171	xanthine dehydrogenase	Homo sapiens	113-116
30113272-11	2018	Samples were stable for at least 5 wk at -80 C, provided residual xanthine oxidoreductase activity was blocked using 0.1 mmol/l oxypurinol.	Oxypurinol	128-138	xanthine dehydrogenase	Rattus norvegicus	66-89
29436218-3	2018	Nitroso sulfamethoxazole and piperacillin activated T cells from all donors, whereas responses to carbamazepine and oxypurinol were only seen in donors expressing HLA-B*15:02 and HLA-B*58:01, respectively.	Oxypurinol	116-126	major histocompatibility complex, class I, B	Homo sapiens	163-168
29436218-3	2018	Nitroso sulfamethoxazole and piperacillin activated T cells from all donors, whereas responses to carbamazepine and oxypurinol were only seen in donors expressing HLA-B*15:02 and HLA-B*58:01, respectively.	Oxypurinol	116-126	major histocompatibility complex, class I, B	Homo sapiens	179-184
29342419-5	2018	Our results show that ABCG2 transports oxypurinol, an active metabolite of allopurinol, whereas allopurinol and febuxostat, a new xanthine dehydrogenase inhibitor, are not substrates of ABCG2.	Oxypurinol	39-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	22-27
29342419-6	2018	The amount of oxypurinol transported by ABCG2 vesicles significantly increased in the presence of ATP, compared to that observed with mock vesicles.	Oxypurinol	14-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	40-45
29342419-7	2018	Since the half-life of oxypurinol is longer than that of allopurinol, the xanthine dehydrogenase-inhibiting effect of allopurinol mainly depends on its metabolite, oxypurinol.	Oxypurinol	23-33	xanthine dehydrogenase	Homo sapiens	74-96
29342419-7	2018	Since the half-life of oxypurinol is longer than that of allopurinol, the xanthine dehydrogenase-inhibiting effect of allopurinol mainly depends on its metabolite, oxypurinol.	Oxypurinol	164-174	xanthine dehydrogenase	Homo sapiens	74-96
27392750-6	2016	Oxypurinol addition to 5 x 103 cells (ranging from 5.0 to 0.0 muM) caused a linear decrease in XO activity, with an IC50 of 1.0 +- 0.5 muM.	Oxypurinol	0-10	latexin	Homo sapiens	62-65
27392750-6	2016	Oxypurinol addition to 5 x 103 cells (ranging from 5.0 to 0.0 muM) caused a linear decrease in XO activity, with an IC50 of 1.0 +- 0.5 muM.	Oxypurinol	0-10	latexin	Homo sapiens	135-138
27106261-7	2016	RESULTS: The numbers of IFN-gamma-releasing cells in allopurinol-allergic subjects were significantly higher than in control subjects when stimulating PBMCs with oxypurinol 100 mug mL-1 , especially when adding anti-PD-L1 supplementation.	Oxypurinol	162-172	interferon gamma	Homo sapiens	24-33
27106261-7	2016	RESULTS: The numbers of IFN-gamma-releasing cells in allopurinol-allergic subjects were significantly higher than in control subjects when stimulating PBMCs with oxypurinol 100 mug mL-1 , especially when adding anti-PD-L1 supplementation.	Oxypurinol	162-172	CD274 molecule	Homo sapiens	216-221
27106261-8	2016	According to the receiver operating characteristic curve results, the optimal discriminatory power of IFN-gamma ELISpot in confirming diagnosis of allopurinol-induced SCARs can be obtained using 16 spot-forming cells per 106 PBMCs as a cut-off value upon oxypurinol/anti-PD-L1 stimulation (79 2% sensitivity and 95 2% specificity).	Oxypurinol	255-265	interferon gamma	Homo sapiens	102-111
27106261-9	2016	CONCLUSIONS: The measurement of oxypurinol/anti-PD-L1-inducing IFN-gamma-releasing cells yields a high diagnostic value in distinguishing between allopurinol-allergic and control subjects.	Oxypurinol	32-42	CD274 molecule	Homo sapiens	48-53
27106261-9	2016	CONCLUSIONS: The measurement of oxypurinol/anti-PD-L1-inducing IFN-gamma-releasing cells yields a high diagnostic value in distinguishing between allopurinol-allergic and control subjects.	Oxypurinol	32-42	interferon gamma	Homo sapiens	63-72
27362322-4	2016	HLA-B58 : 01 has been found to be strongly associated with allopurinol-SCARs with functional interactions between allopurinol/its metabolite-oxypurinol and the T-cell receptor (TCR).	Oxypurinol	141-151	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	160-175
27362322-4	2016	HLA-B58 : 01 has been found to be strongly associated with allopurinol-SCARs with functional interactions between allopurinol/its metabolite-oxypurinol and the T-cell receptor (TCR).	Oxypurinol	141-151	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	177-180
27362322-9	2016	Activation of specific T cells with preferential TCR and its functional interaction of HLA-B58 : 01 molecule and allopurinol/oxypurinol are involved in the immune mechanism of allopurinol-induced SCAR.	Oxypurinol	125-135	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	49-52
26416594-5	2016	The interactions between allopurinol, its metabolite, oxypurinol, and T cells have been studied, and evidence exists that the presence of the HLA-B(*)58:01 allele and a high concentration of oxypurinol function synergistically to increase the number of potentially immunogenic-peptide-oxypurinol-HLA-B(*)58:01 complexes on the cell surface, thereby increasing the risk of T-cell sensitization and a subsequent adverse reaction.	Oxypurinol	54-64	major histocompatibility complex, class I, B	Homo sapiens	142-147
26416594-5	2016	The interactions between allopurinol, its metabolite, oxypurinol, and T cells have been studied, and evidence exists that the presence of the HLA-B(*)58:01 allele and a high concentration of oxypurinol function synergistically to increase the number of potentially immunogenic-peptide-oxypurinol-HLA-B(*)58:01 complexes on the cell surface, thereby increasing the risk of T-cell sensitization and a subsequent adverse reaction.	Oxypurinol	191-201	major histocompatibility complex, class I, B	Homo sapiens	296-301
26416594-5	2016	The interactions between allopurinol, its metabolite, oxypurinol, and T cells have been studied, and evidence exists that the presence of the HLA-B(*)58:01 allele and a high concentration of oxypurinol function synergistically to increase the number of potentially immunogenic-peptide-oxypurinol-HLA-B(*)58:01 complexes on the cell surface, thereby increasing the risk of T-cell sensitization and a subsequent adverse reaction.	Oxypurinol	191-201	major histocompatibility complex, class I, B	Homo sapiens	296-301
27119840-4	2016	It has been established that Q141K polymorphism can directly modulate BCRP-mediated allopurinol and oxypurinol efflux, the K allele is associated with a lower reduction in serum uric acid in response to allopurinol treatment.	Oxypurinol	100-110	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	70-74
25946710-0	2015	Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions.	Oxypurinol	0-10	granulysin	Homo sapiens	76-86
25946710-5	2015	Oxypurinol stimulation resulted in a significant increase in granulysin in the cultures of blood samples from SCAR patients (n=14) but not tolerant controls (n=11) or healthy donors (n=23).	Oxypurinol	0-10	granulysin	Homo sapiens	61-71
25946710-8	2015	Preferential TCR-V-beta usage and clonal expansion of specific CDR3 (third complementarity-determining region) were found in the blister cells from skin lesions (n=8) and oxypurinol-activated T-cell cultures (n=4) from patients with allopurinol-SCAR.	Oxypurinol	171-181	CDR3	Homo sapiens	63-67
25946710-9	2015	These data suggest that, in addition to HLA-B*58:01, clonotype-specific T cells expressing granulysin upon oxypurinol induction participate in the pathogenesis of allopurinol-induced SCAR.	Oxypurinol	107-117	granulysin	Homo sapiens	91-101
25698503-3	2015	The present review deals with some unique observation regarding the structure, function and reactivity of some models and native proteins in rationalizing the choice of diverse substrates in seemingly similar enzymes such as Nap (nitrate reductase) and Fdh (formate dehydrogenase) and the dual form of a specific substrate of an enzyme like trimethylamine N-oxide reductase (TAMOR) and providing the electronic reason for the inhibition in the oxypurinol-inhibited xanthine oxidase (XO).	Oxypurinol	444-454	aldehyde dehydrogenase 1 family member L1	Homo sapiens	253-256
25698503-3	2015	The present review deals with some unique observation regarding the structure, function and reactivity of some models and native proteins in rationalizing the choice of diverse substrates in seemingly similar enzymes such as Nap (nitrate reductase) and Fdh (formate dehydrogenase) and the dual form of a specific substrate of an enzyme like trimethylamine N-oxide reductase (TAMOR) and providing the electronic reason for the inhibition in the oxypurinol-inhibited xanthine oxidase (XO).	Oxypurinol	444-454	aldehyde dehydrogenase 1 family member L1	Homo sapiens	258-279
25326127-7	2015	Oxypurinol and Tempol diminished the leak in NOS1(-/-) cardiomyocytes.	Oxypurinol	0-10	nitric oxide synthase 1, neuronal	Mus musculus	45-49
24506204-4	2014	After partial protein purification, the enzyme responsible for retinoic acid biosynthesis was identified and quantified as XDH by immunoassay, by its ability to oxidize xanthine to uric acid and its sensitivity to the inhibitory effect of oxypurinol.	Oxypurinol	239-249	xanthine dehydrogenase	Homo sapiens	123-126
24899662-11	2014	Oxypurinol was a substrate for purified MPO that enhanced the oxidation of urate.	Oxypurinol	0-10	myeloperoxidase	Homo sapiens	40-43
24658348-9	2014	The inhibition of xanthine oxidoreductase by oxypurinol attenuated the acute hypotensive effects of nitrite.	Oxypurinol	45-55	xanthine dehydrogenase	Rattus norvegicus	18-41
24591375-0	2014	Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01.	Oxypurinol	0-10	major histocompatibility complex, class I, B	Homo sapiens	100-105
24591375-4	2014	To understand the interactions among the drug, HLA, and TCR, we generated T cell lines that react to ALP or its metabolite oxypurinol (OXP) from HLA-B*58:01(+) and HLA-B*58:01(-) donors and assessed their reactivity.	Oxypurinol	123-133	major histocompatibility complex, class I, B	Homo sapiens	145-150
24406683-4	2014	To this end, XOR inhibition has been accomplished with application of classic pyrazolopyrimidine-based inhibitors allo/oxypurinol or the newly FDA-approved XOR-specific inhibitor, Uloric  (febuxostat).	Oxypurinol	119-129	xanthine dehydrogenase	Homo sapiens	13-16
24296267-4	2014	Among the two NO release peaks we found in UVA exposed HaCaT cells, XO inhibitor oxypurinol was found to be able to inhibit NO release at 3h post UVA exposure but not 18h, while iNOS inhibitor S-methylisothiourea sulfate (SMT) was found to inhibit iNOS expression and NO release at 18h but not 3h.	Oxypurinol	81-91	nitric oxide synthase 2	Homo sapiens	248-252
24152157-6	2013	We generated allopurinol or oxypurinol-specific T cell lines (ALP/OXP-TCLs) from allopurinol naive HLA-B*58:01(+) and HLA-B*58:01(-) individuals using various drug concentrations.	Oxypurinol	28-38	ATHS	Homo sapiens	62-65
24152157-13	2013	CONCLUSIONS AND CLINICAL RELEVANCE: This study establishes the important synergistic role of drug concentration and HLA-B*58:01 allele in the allopurinol or oxypurinol-specific T cell responses.	Oxypurinol	157-167	major histocompatibility complex, class I, B	Homo sapiens	116-121
24152157-14	2013	Despite the prevailing dogma that Type B adverse drug reactions are dose independent, allopurinol hypersensitivity is primarily driven by oxypurinol-specific T cell response in a dose-dependent manner, particular in the presence of HLA-B*58:01 allele.	Oxypurinol	138-148	major histocompatibility complex, class I, B	Homo sapiens	232-237
23660190-11	2013	Poly IC-induced upregulation of B7-H1 was attenuated by N-acetyl-L-cysteine, an antioxidant, or by oxypurinol, an inhibitor of xanthine oxidase.	Oxypurinol	99-109	CD274 molecule	Homo sapiens	32-37
22398104-7	2012	Recent studies have renewed attention to the xanthine oxidoreductase system, since xanthine oxidoreductase inhibitors, such as allopurinol and oxypurinol, would be capable of preventing atherosclerosis progression by reducing endothelial dysfunction.	Oxypurinol	143-153	xanthine dehydrogenase	Homo sapiens	45-68
22398104-7	2012	Recent studies have renewed attention to the xanthine oxidoreductase system, since xanthine oxidoreductase inhibitors, such as allopurinol and oxypurinol, would be capable of preventing atherosclerosis progression by reducing endothelial dysfunction.	Oxypurinol	143-153	xanthine dehydrogenase	Homo sapiens	83-106
22000995-3	2012	We previously found that the combined treatment with oxypurinol - as inhibitor of xanthine oxidase- and pentoxifylline - as inhibitor of TNF-alpha production-restrained local and systemic inflammatory response and decreased mortality in experimental acute pancreatitis.	Oxypurinol	53-63	tumor necrosis factor	Rattus norvegicus	137-146
22000995-8	2012	The beneficial effects of oxypurinol in the inflammatory response may also be ascribed to a partial inhibition of MEK1/2 activity.	Oxypurinol	26-36	mitogen activated protein kinase kinase 1	Rattus norvegicus	114-120
23029301-9	2012	Whereas oxypurinol was associated with higher GPx1, MnSOD, CAT, XDH, MURF1, MAFbx and UbB mRNA compared to control (P<=0.05).	Oxypurinol	8-18	glutathione peroxidase 1	Mus musculus	46-50
23029301-9	2012	Whereas oxypurinol was associated with higher GPx1, MnSOD, CAT, XDH, MURF1, MAFbx and UbB mRNA compared to control (P<=0.05).	Oxypurinol	8-18	superoxide dismutase 2, mitochondrial	Mus musculus	52-57
23029301-9	2012	Whereas oxypurinol was associated with higher GPx1, MnSOD, CAT, XDH, MURF1, MAFbx and UbB mRNA compared to control (P<=0.05).	Oxypurinol	8-18	catalase	Mus musculus	59-62
23029301-9	2012	Whereas oxypurinol was associated with higher GPx1, MnSOD, CAT, XDH, MURF1, MAFbx and UbB mRNA compared to control (P<=0.05).	Oxypurinol	8-18	xanthine dehydrogenase	Mus musculus	64-67
23029301-9	2012	Whereas oxypurinol was associated with higher GPx1, MnSOD, CAT, XDH, MURF1, MAFbx and UbB mRNA compared to control (P<=0.05).	Oxypurinol	8-18	tripartite motif-containing 63	Mus musculus	69-74
23029301-9	2012	Whereas oxypurinol was associated with higher GPx1, MnSOD, CAT, XDH, MURF1, MAFbx and UbB mRNA compared to control (P<=0.05).	Oxypurinol	8-18	F-box protein 32	Mus musculus	76-81
23029301-9	2012	Whereas oxypurinol was associated with higher GPx1, MnSOD, CAT, XDH, MURF1, MAFbx and UbB mRNA compared to control (P<=0.05).	Oxypurinol	8-18	ubiquitin B	Mus musculus	86-89
21224483-7	2011	Finally, treatment of STZ mice, as well as high-fat and high-sucrose diet-fed mice, with oxypurinol reduced markers of systemic and muscular oxidative stress and prevented structural and functional mitochondrial alterations, confirming the in vivo relevance of XO in ROS production in diabetic mice.	Oxypurinol	89-99	xanthine dehydrogenase	Mus musculus	261-263
19828843-5	2010	Mice treated with the XO inhibitor oxypurinol showed a smaller increase in superoxide anions in muscle microdialysates following contractions than in microdialysates from muscles of vehicle-treated mice.	Oxypurinol	35-45	xanthine dehydrogenase	Mus musculus	22-24
19564319-11	2009	In fetuses/newborns with therapeutic allopurinol/oxypurinol concentrations in cord blood, lower plasma levels of the brain injury marker protein S-100B were detected.	Oxypurinol	49-59	S100 calcium binding protein B	Homo sapiens	145-151
19299643-6	2009	The XO inhibitor oxypurinol was administered to CryAB(R120G) mice for a period of 1 or 3 months.	Oxypurinol	17-27	crystallin, alpha B	Mus musculus	48-53
19371603-7	2009	The increase in MMP production was abolished by pre-treatment with the antioxidants Tiron and N-acetyl cysteine (NAC) or with the xanthine oxidase inhibitors allopurinol or oxypurinol.	Oxypurinol	173-183	matrix metallopeptidase 9	Mus musculus	16-19
19371603-7	2009	The increase in MMP production was abolished by pre-treatment with the antioxidants Tiron and N-acetyl cysteine (NAC) or with the xanthine oxidase inhibitors allopurinol or oxypurinol.	Oxypurinol	173-183	xanthine dehydrogenase	Mus musculus	130-146